Influence of recurrent vulvovaginal candidiasis on quality of life issues

Vulvovaginal candidiasis is a common fungal infection caused by Candida Sp, especially Candida albicans. Recurrent vulvovaginal candidiasis was defined as the occurrence of four or more episodes of vulvovaginal candidiasis in 12 months period. As many as 9% of women from various populations have recurrent vulvovaginal candidiasis. Vulvovaginal candidiasis affects the quality of life, mental health, and sexual activity. There are many predisposing factors that caused recurrent vulvovaginal candidiasis, such as genetics, host, habit, idiopathic and non-albican candida microbes. Management of recurrent vulvovaginal candidiasis includes elimination of predisposing factors; mycological culture diagnosis and identification of specific Candida species; followed by microbiological examination to confirm the sensitivity of the azole group to Candida sp. Further, oral, or topical therapy should be continued until the patient is asymptomatic and culture-negative. Patients should receive induction therapy followed by maintenance suppressive therapy for six months.

Download Full-text

Recurrent Vulvovaginal Candidiasis

BioScientia Medicina ◽

10.32539/bsm.v5i3.280 ◽

2021 ◽

Vol 5 (3) ◽

pp. 498-507

Author(s):

Cyntya Sari Sovianti ◽

Mutia Devi

Keyword(s):

Quality Of Life ◽

Mental Health ◽

Topical Therapy ◽

Predisposing Factors ◽

Vulvovaginal Candidiasis ◽

Suppressive Therapy ◽

Recurrent Vulvovaginal Candidiasis ◽

Candida Sp ◽

Culture Negative

Vulvovaginal candidiasis is a common fungal infection caused by Candida Sp,especially Candida albicans. Recurrent vulvovaginal candidiasis was defined asthe occurrence of four or more episodes of vulvovaginal candidiasis in 12 monthsperiod. As many as 9% of women from various populations have recurrentvulvovaginal candidiasis. Vulvovaginal candidiasis affects the quality of life,mental health, and sexual activity. There are many predisposing factors thatcaused recurrent vulvovaginal candidiasis, such as genetics, host, habit,idiopathic and non-albican candida microbes. Management of recurrentvulvovaginal candidiasis includes elimination of predisposing factors; mycologicalculture diagnosis and identification of specific Candida species; followed bymicrobiological examination to confirm the sensitivity of the azole group toCandida sp. Further, oral, or topical therapy should be continued until the patientis asymptomatic and culture-negative. Patients should receive induction therapyfollowed by maintenance suppressive therapy for six months.

Download Full-text

Use of fluconazole in women of reproductive age with vulvovaginal candidiasis

Medical Council ◽

10.21518/2079-701x-2018-13-96-102 ◽

2018 ◽

pp. 96-102

Author(s):

E. A. Mezhevitinova ◽

P. R. Abakarova ◽

Sh. M. Pogosyan

Keyword(s):

Quality Of Life ◽

Vulvovaginal Candidiasis ◽

Reproductive Age ◽

Common Disease ◽

Women Of Reproductive Age ◽

Recurrent Vulvovaginal Candidiasis ◽

Group I ◽

Relapse Therapy

Topicality: vulvovaginal candidiasis (VVC) is a common disease caused by the infectious damage of the vulva and vagina by yeast-like fungi from Candida genus. According to the literature, a VVC episode occurs in 75% of women, and 5-8% of them get a recurring course of the disease. Frequent recurrences of the disease may result in the psychosexual disorder and reduce the women’s quality of life and recurrent vulvovaginal candidiasis (VVC) therapy is still a very difficult task.Purpose of the study: evaluate the efficacy of fluconazole (150 mg) in acute and recurrent vulvovaginal candidiasis.Materials and methods:A total of 89 women of reproductive age with acute and recurrent HCV were enrolled in the study, which were subdivided into 2 groups: the first group included women with acute vulvovaginal candidiasis (AVVC) (n = 51), and the second group - women with recurrent vulvovaginal candidiasis (RVVC) (n = 38). The Group I (AVVC) received fluconazole 150 mg once. Depending on the prescribed therapy, the second group (RVVC) was subdivided into two subgroups: patients in the IIa subgroup received fluconazole 150 mg intravenously, three times, at intervals of 2 days, and women in the IIb subgroup received fluconazole 150 mg for a period of 6 months in addition to the three-fold intake of fluconazole weekly. The follow-up period was 6 months after the end of therapy, during which the frequency of VVC recurrence and the effectiveness of the therapy was evaluated.Results of the study: our data showed that all patients with acute VVC had a discontinuation of symptoms of the disease and a normalization of laboratory parameters after treatment with fluconazole, and after the anti-relapse therapy course the incidence of VVC recurrences was significantly lower compared to the period before anti-relapse therapy (p = 0.038). It was shown that all the investigated strains of C. albicans (100%) were sensitive to fluconazole, and resistance was detected only in 1 strain of C. glabrata and 1 strain of C. krusei.

Download Full-text

Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis

Health and Quality of Life Outcomes ◽

10.1186/s12955-016-0470-2 ◽

2016 ◽

Vol 14 (1) ◽

Cited By ~ 20

Author(s):

Yu-Xia Zhu ◽

Ting Li ◽

Shang-Rong Fan ◽

Xiao-Ping Liu ◽

Yi-Heng Liang ◽

...

Keyword(s):

Quality Of Life ◽

Short Form ◽

Vulvovaginal Candidiasis ◽

Health Related Quality ◽

Short Form 36 ◽

Recurrent Vulvovaginal Candidiasis ◽

Sf 36 ◽

Related Quality ◽

Health Related

Download Full-text

Optimization of treatment of recurrent vulvovaginal candidiasis

Medical alphabet ◽

10.33667/2078-5631-2019-2-14(389)-27-30 ◽

2019 ◽

Vol 2 (14) ◽

pp. 27-30

Author(s):

L. V. Tkachenko ◽

N. I. Sviridova ◽

L. N. Bogatyryova ◽

I. A. Gritsenko

Keyword(s):

Quality Of Life ◽

Menstrual Cycle ◽

Comparison Group ◽

Vulvovaginal Candidiasis ◽

Menstrual Cycles ◽

Recurrent Vulvovaginal Candidiasis ◽

The Mean ◽

Efficacy Of Treatment ◽

Consecutive Cycle

The purpose of the study was to evaluate the efficacy of treatment of recurrent drug Orungamin depending on the time of occurrence of relapse.Material and methods. 62 women with recurrent candida vulvovaginit is were examined and treated. The mean age of the patients was 35.6 ± 0.7 years. The main group consisted of 32 patients who in the premenstrual period 5 days before the expected date of menstruation were prescribed Orungamin 1 capsule (100 mg) twice a day (200 mg) for 3 days during three consecutive menstrual cycles. The comparison group included women receiving Orungamin three consecutive cycle 3 day 1 capsule (100 mg) 2 times a day, without regard to days of the menstrual cycle.Results. Therapy with Orungamin 100 mg twice a day during the premenstrual period not only helped to increase the effectiveness of the treatment of relapses, but also the quality of life of patients.

Download Full-text

Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease

10.1093/oso/9780195169850.001.0001 ◽

2006 ◽

Keyword(s):

Quality Of Life ◽

Sickle Cell Disease ◽

Childhood Cancer ◽

Children And Adolescents ◽

Peer Relationships ◽

Sickle Cell ◽

Cell Disease ◽

Life Issues ◽

Art Research

Over recent decades, tremendous advances in the prevention, medical treatment, and quality of life issues in children and adolescents surviving cancer have spawned a host of research on pediatric psychosocial oncology. This important volume fulfills the clear need for an up-to-date, comprehensive handbook for practitioners that delineates the most recent research in the field--the first of its kind in over a decade. Over 60 renowned authors have been assembled to provide a thorough presentation of the state-of-the art research and literature, with topics including: -Neuropsychological effects of chemotherapy and radiation therapy -Bone marrow transplantation -Important issues about quality of life during and following treatment -Collaborative research among child-focused psychologists -Standards of psychological care for children and adolescents -Stress and coping in the pediatric cancer experience -The role of family and peer relationships The Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease represents both multidisciplinary and international efforts, an alliance between physicians and parents, and a combination of research and service. With a wealth of information of great interest to patients and their families, this volume will also be a welcome resource to the psychologists, psychiatrists, pediatricians, oncologists, nurses, and social workers who confront these issues as they help children and their families through the treatment, recovery, and grieving processes.

Download Full-text

COVID-19 and Quality of Life: Twelve Reflections

Applied Research in Quality of Life ◽

10.1007/s11482-020-09898-z ◽

2021 ◽

Author(s):

Daniel T. L. Shek

Keyword(s):

Quality Of Life ◽

Digital Divide ◽

Well Being ◽

Sudden Onset ◽

Economic Disadvantage ◽

Conflict Prevention ◽

Collective Rights ◽

The World ◽

Life Issues

AbstractCOVID-19 has severely affected the world since December 2020. Because of its sudden onset and highly contagious nature, the world has responded in a “crisis management” manner. With effective vaccines almost available, it is appropriate at this time to have some reflections about COVID-19 in relation to the quality of life issues. In this paper, we highlight twelve issues for reflection, which can help us better prepared for future pandemics. These include: digital divide, health inequality, gender inequality, economic disadvantage, family well-being, impact on holistic well-being, economic development versus saving lives, consumption versus environmental protection, individual rights versus collective rights, international collaboration versus conflict, prevention of negative well-being, and promotion of positive well-being.

Download Full-text